Welcome to the Helus Pharma Phase III APPROACH Topline Results. Before we get started today, I would like to remind everyone that certain statements in this presentation are forward-looking statements and are prospective in nature. In preparing these forward-looking statements, several assumptions were made by Helus, and there are risks that actual results obtained by the company will differ materially from these statements. The company cannot guarantee that any forward-looking statement will materialize, and you are cautioned not to place undue reliance on them. We refer current and potential investors to certain cautionary statements contained in the presentation and to the forward-looking information and risk factor sections of the company's annual information form and the most recently filed management's discussion and analysis available at sedarplus.ca and on EDGAR at sec.gov. Forward-looking statements represent the company's expectations as of November 16th, 2026.
Except as required by securities laws, the company does not undertake any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise. Presenting on today's call are Michael Halstead, Chief Executive Officer, and Amir Inamdar, Chief Medical Officer of Helus Pharma. As a reminder, this call is being recorded and will be available for replay on the company's website. I would now like to hand the conference over to Michael Halstead, Chief Executive Officer of Helus Pharma.
Good morning, everyone, and thank you for joining us. Today is a defining moment for our company and a major milestone in the development of HLP003. We are very pleased to report positive topline results from the APPROACH study evaluating 003 as an adjunctive treatment for major depressive disorder. This study achieved its primary endpoint and key secondary endpoint with an impressive treatment effect and a favorable safety and tolerability profile. Several elements of the dataset stand out. First, the antidepressant effect was both clinically meaningful and robust, demonstrating substantial improvement in patients who had an inadequate response to their previously prescribed antidepressant medication. A 7.6 MADRS improvement over placebo was observed at the primary endpoint of six weeks. Second, the treatment effect emerged rapidly, as early as day two, and was durable through 12 weeks following two administrations with a seven-point MADRS improvement over placebo.
Third, the response and remission rates are particularly impressive. In major depressive disorder, remission is the outcome clinicians and patients strive to achieve, and the proportion of patients reaching remission in this study underscores the potential clinical significance of these results. Finally, these efficacy outcomes were accompanied by a favorable safety and tolerability profile that was consistent with our prior studies. Taken together, we believe APPROACH demonstrates the type of efficacy, durability, and tolerability that could meaningfully differentiate 003 as a new and important adjunctive treatment option for patients living with depression. This is important, as depression is a highly prevalent condition with unmet needs. Approximately 22 million people are living with MDD in the U.S. Of the millions of people being treated for depression, approximately two-thirds of patients do not achieve remission with first-line treatment.
As a result, clinicians often add treatments on to standard of care to build on the partial response and help patients progress towards remission. Based on the APPROACH data results, we believe HLP003 has the potential to set a new benchmark in the adjunctive treatment of MDD. This is particularly apparent in light of the efficacy and tolerability limitations of the five currently approved adjunctive treatments for MDD. These are the atypical antipsychotics. These antipsychotic treatments offer a modest benefit and are associated with side effects, including weight gain, cardiometabolic dysfunction, and movement disorders. Therefore, there remains a clear need for medicines that can deliver rapid and meaningful efficacy while being well tolerated. With that, I'll turn the call over to Amir, who will review the results in more detail before we open the call for questions.
Thanks, Michael. We are very excited about these study results, given the significant unmet need in adjunctive treatment of MDD. I'll begin with the study design. This is a randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of HLP003 as an adjunctive treatment in adult patients with MDD. Patients enrolled in this study were on a stable background dose of an antidepressant and were randomized to receive two administrations of either 16 milligrams of HLP003 or inactive placebo. The first administration was on day one, and the second, three weeks after. Patients stayed on a stable background dose of their antidepressant medication for the entire duration of the study. The primary endpoint was mean change from baseline versus placebo on the MADRS total score at week six. The key secondary endpoint was mean change from baseline in the MADRS total score at week 12.
The study enrolled adults who met DSM-5 criteria for MDD and were symptomatic despite treatment with an adequately dosed antidepressant. Participants were required to have moderate to severe depressive symptoms, reflected by a MADRS score of at least 24 and a CGI score of at least four at both the screening and baseline, and were having an inadequate response to the current antidepressant treatment. Patients with treatment-resistant depression, psychotic disorders, bipolar disorder, clinically significant suicidality, substance use disorder, or recent psychedelic exposure were excluded. Turning to demographics and baseline characteristics. The treatment groups were well-balanced. The average age was about 45 years. The majority of participants were female, and the mean baseline MADRS score of approximately 33 reflected a population with moderate to severe depression. Let's now discuss the efficacy results. Treatment with HLP003 demonstrated rapid, robust, durable, and clinically meaningful antidepressant effects across multiple endpoints.
At the primary endpoint of week six, HLP003 demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms compared with placebo. The LS mean reduction from baseline in the MADRS total score for HLP003 was 19.5 points versus 11.9 points for placebo. That is a 7.6-point placebo-adjusted reduction with a p-value of less than 0.0001 and an effect size of 0.65. Equally important, the treatment effect was sustained through week 12, the key secondary endpoint. Patients treated with HLP003 continued to demonstrate improvement, achieving a LS mean treatment difference of 7 points versus placebo, with a p-value of less than 0.0001, with an effect size of 0.58. The onset was rapid, with treatment effects emerging as early as day two. It was statistically significant and maintained at every subsequent assessment through week 12, supporting both the rapid and durable treatment benefit.
Beyond mean changes in symptoms, we also evaluated outcomes that are particularly meaningful to patients and clinicians, response and remission. At week 6, 56% of patients receiving HLP003 were responders. Response was defined as at least a 50% reduction in MADRS score. Through week 12, response rates remained robust, with 45% patients on 003 still having at least a 50% improvement. Even more notable were the remission rates. Approximately 51% of patients achieved remission at week six. We used the conventional definition of remission, which is a MADRS score of 10 or less. Remission rates remained high through week 12, with 40% of patients still in remission. Both response and remission were rapidly achieved, with half of the patients on 003 achieving a response and 39% of patients reaching remission as early as day two, the day after dosing. Remission is ultimately the goal of treatment.
These findings suggest that a substantial proportion of patients were not simply improving, but returning to a level of functioning associated with minimal depressive burden. This data is further supported by statistically significant results in the global assessment of clinical symptoms in this trial. The Clinical Global Impression Scale rates a clinician's overall assessment of illness and closely aligns with clinical practice. 003 demonstrated statistically significant improvements on CGI-S compared with placebo at both week six and week 12. While efficacy and durability are paramount, an equally important aspect of any treatment is the safety and tolerability profile. Let me walk you through the safety data from the study. 003 exhibited a favorable safety and tolerability profile. This table lists adverse events that were reported in at least 10% of the participants. Most adverse events were mild to moderate in intensity, occurred on and resolved on the day of dosing.
There were no unexpected safety findings observed in this study. There were three treatment-related serious adverse events reported with 003. One of these was a suicide attempt by a participant who was a non-responder to treatment. This attempt occurred 55 days after the participant received the second dose of 003. The participant was admitted to the hospital two days after an overdose of their background antidepressant medication and was subsequently discharged. While suicidality is a feature of depression, based on a comprehensive assessment of the APPROACH data, including the Columbia Suicide Severity Rating Scale, we did not observe a signal of suicidality, which would require statistical disproportionality, a clear temporal relationship between the drug and the event, and exclusion of potential confounding factors, among others.
In summary, these results demonstrate a rapid, robust, and durable antidepressant effect that was consistently reflected across symptom improvement, response, remission, and clinician-rated measures of disease severity. HLP003 was well tolerated, and most reported AEs mild to moderate and confined to the day of dosing. As a psychiatrist who has spent many years caring for patients, I believe these findings suggest the potential for HLP003 to become an important treatment option for patients with MDD and support our confidence as we continue to execute our phase III program. Michael, I'll turn the call back over to you.
Thank you, Amir. Looking ahead, we remain focused on disciplined execution and the continued advancement of the HLP003 program. The EMBRACE study, our second phase III efficacy study, is ongoing. We expect results from EMBRACE in the fourth quarter of next year. In addition, the EXTEND trial, our long-term extension study, is also ongoing. I would also note that HLP003 has received breakthrough therapy designation from FDA. We are very proud of the Helus team that made this achievement possible, and we thank the participants, investigators, and the clinical sites who participated in this study. The APPROACH study delivered what we believe are highly compelling results across efficacy, durability, and tolerability measures, and position HLP003 as a potential important option for the adjunctive treatment of MDD. We look forward to updating you on our progress in the months ahead. With that, operator, please open the line for questions.
To ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. In the interest of time, we ask that you please limit yourself to one question and one follow-up. Please stand by while we compile the Q&A roster. Our first question comes from Ritu Baral with TD Cowen. Your line is open.
Good morning, guys, and congratulations on this data. Really, really impressive remission rates here. As we look at the overall therapeutic profile, I was wondering if you had any additional detail on the suicide attempt. It sounds like you guys are unblinded to these events, and that all three occurred. Is this true that you are unblinded and three occurred in the treatment group? Also, insofar as that suicide attempt, do you have any background additional demographic patient information that you can share, like what their experience during treatment was? Like, did clinicians know that this patient may have an unusual response baseline, any demographic information? Then I have an efficacy follow-up.
Sure. Thanks, Ritu. Yes, we are very excited about the data that we provided everyone today. In terms of safety and tolerability, of course, we saw a favorable safety and tolerability profile in this study. As we said, most of the events were mild to moderate, transitory around day of treatment. We did see the three SAEs, and in terms of the attempt, Amir, you want to provide any additional color on that?
Yeah, absolutely. We saw one attempt in the trial. As I said, while suicidality is a feature of depression, based on our comprehensive assessment of the APPROACH data, which included also the C-SSRS, the Columbia Suicide Severity Rating Scale, we have not observed a signal of suicidality. That would require statistical disproportionality, a temporal relationship between drug and the event, and exclusion of potential confounding factors, among other things. There were multiple factors that support the determination that this case does not represent a signal. These factors include, the participant had an underlying major depressive disorder, which itself carries a background risk of suicidality. They had a prior history of suicide attempt. The participant was receiving concomitant antidepressant that has a boxed warning for suicidality. In addition, the event occurred approximately seven weeks after the last dose, weakening the temporal association.
No similar serious cases were identified in the APPROACH study. Taken together, these factors do not support a suicidality signal with respect to a suicide attempt, which is a feature of depression. We also did not find a signal of suicidality in the study, including an assessment on the Columbia.
Very helpful. Then moving to efficacy, you mentioned, back on the remission rates, that 39% in the active arm had remitted at day two following the second treatment, and that 40% remained in remission at week 12, with a 51% at week six. Was there significant overlap between the 39% that remitted at day two and the 40% that remained in remission at week 12?
Sure, Ritu. I'll let Amir speak to the specifics. Just to be very clear on day two, right, patient receives a dose on day one of the study, and the remission rates are on the second day of the study, right? So one dose, 24 hours later, we're seeing these very strong remission rates. I just want to make sure that everyone understands what day two represents. Go ahead, Amir.
Yeah. We will, as part of the fuller dataset, look at something that you call as a sustained remission or response rates. But as Michael said, one day after dosing, 39% of patients are in remission. At the 12-week time point, you go to the 40%. What I also want to point out that in all the intervening time point, the difference between active and placebo on remission rates was statistically significant. That significance continued throughout the duration of the study.
I think it's just really an impressive thing. Clinicians and patients have this very rapid benefit in terms of the response and remission, and then for that to have been durable out to 12 weeks, Ritu, we're very excited about this. It's just really important in terms of the potential patient benefit here.
The sustained statistical significance at each time point, does that imply that most of the patients are the same patients? It's not that you have certain people who remit early and then fall out, and other people who sort of fall into, or achieve, rather, remission later, closer to the week 12?
The way you look at sustained remission is, if somebody goes into remission, do they still stay in remission at the last time point, which is the 12 weeks? The standard definition typically allows for one excursion during that period. We have not formally looked at that, and that will be part of the next set of data that we will disclose. But as I said, once we saw statistically significant result in the remission rates, that statistical significance continued out to the 12 weeks time point.
Understood. Thank you.
Thank you, Ritu.
Thank you. Our next question comes from Andrew Tsai with Jefferies. Your line is open.
Hey, guys. This is John on for Andrew. Congrats on the data. Just kind of building more on the response remission rate, they really do appear quite impressive. Maybe if you can just speak to how the response and remission rates may compare to other psychedelics in the field, with the caveat that maybe they're pursuing other depression indications, as well as typical adjunct MDD drugs. Thanks.
Sure. I will let Amir speak more generally. First, I have to emphasize, this is an adjunctive trial, right? You are adding HLP003 on top of patients are on their baseline standard of care throughout the trial. Then getting usually some partial benefit, right? Not sufficient benefit, but some benefit. We are showing these effects on top of that. It just really, really impressive results with that context. As then you think about what the right comparison is, of course, it is other adjunctive trials for the treatment of MDD, and there are only the five medications that are indicated adjunctively, and that is the atypical antipsychotics. That is the correct comparison. That is absolutely how clinicians evaluate data, right? Then if separately, to look at the peers, I always try and be clear, I view them as peers in the psychedelic space.
I hope they do well and build awareness for the category, build infrastructure, but they are all pursuing different indications. None of those are focused on the adjunctive treatment of MDD. They are all effectively monotherapy-type indications. Again, the comparison is really not appropriate. If you do do that comparison, nonetheless, these remission and response rates are better. They are again, doing cross comparisons. I really caution against that, but these response and remission rates are just excellent and, yes, better than anything else that has been seen in the psychedelic category. Amir, do you want to probably add to this as well?
No, I think you summarized it perfectly. It is not an apples to apples comparison when you look at comparing, let us say, adjunctive with monotherapy. But if you do want to make that comparison, you will see that our response and remission rates at the primary endpoint are better. I would not put a number on it, but they are better. You can do the comparison yourself.
Markedly better, yes.
Great. Then one follow-up if I can. I was curious just as it pertains to the SAEs in the drug arm, are you able to share maybe what the rates of SAEs were in the placebo arm, if available? Thanks.
We did not see any serious adverse events in the placebo arm.
Great. Thanks so much. Congrats again.
Thank you.
Thank you. Our next question comes from Pete Stavropoulos with Cantor Fitzgerald. Your line is open.
Good morning, and big congratulations on the data. Truly impressive outcomes. Sticking with the theme, can you just help us parse out the MADRS reduction versus responder/remitter rates, and how those will be viewed by regulators as well as clinicians? Many investors are focused on the MADRS separation, but how should we think about the responder and remission rates, and how will physicians think about these?
Sure. Thanks, Pete. Appreciate the questions. Of course, we're very pleased with the MADRS improvements that are shown here both at six and 12 weeks. I think you correctly point out that there are also other critical factors that are relevant to clinicians, right? Efficacy, then durability of effect. Obviously, the durability that we saw out to the secondary endpoint of 12 weeks, we're very pleased with that. Then the third piece, the safety and tolerability profile here, most of the adverse events, mild to moderate, transitory on the day of treatment.
You put that whole profile together, we believe it'll be very compelling for clinicians, especially when clinicians, they're looking to treat a patient adjunctively, as many clinicians do, and they're looking at, what are my adjunctive treatment options? Currently, they only have the five atypical antipsychotics, with the modest efficacy that they have, together with the side effect profiles, compared to the results that we've demonstrated to date. We believe that clinicians will view those very favorably. Amir, anything additional?
I mean, the only thing I'd add is the responder and remitter rates, when you look at those, they are not just impressive, but they are evident as early as the day after dosing. They remain significant throughout the duration of the trial. What that tells me as a clinician is patients are getting better swiftly, and they remain better. I am very excited about that early onset of improvement and the fact that patients, once they improve, they likely stayed that way throughout the duration of the study.
All right. Thank you for that. Just a follow-up question for EXTEND. What triggers redosing or dosing? Can you help us understand why you chose that trigger? Through your market research, is it a level of severity, a threshold where healthcare practitioners will likely recommend to patients another dosing session?
Yeah. So, in EMBRACE, we've chosen criteria that would typically be reflective of a patient. Sorry, in EXTEND, for redosing, the criteria that would be typically considered by a clinician when they think of redosing a patient. These are predefined in the protocol. These are based on symptom severity as well as a clinician's assessment of whether a patient needs treatment. Based on that, in EXTEND, we allow up to three additional treatments. That will provide us with the information around the durability of treatment effects, as well as the need for retreatment and the retreatment interval. All of these are data that clinicians would typically need when they want to prescribe and manage a patient in the clinic.
Excellent. Thank you for all the coloring, and congratulations once again on these great outcomes.
Thank you, Pete.
Thank you.
Thank you. Our next question comes from Sumant Kulkarni with Canaccord Genuity LLC. Your line is open.
Good morning. Thanks for taking our questions, and nice to see these data. You gave a lot of detail on the patient with the suicide attempt, but on the C-SSRS, especially on the temporal relationship, given the durability of efficacy of this product is relatively long, what would be a good temporal relationship to ensure that the event might not be considered treatment-related in the real world? Then I have a follow-up.
So, that's a matter often of clinical judgment for a clinician, right? In a non-responding patient, like we saw in this study, the one attempt, an event occurring seven weeks after, that is not a clear temporal relationship. Something typically occurring within days of dosing would be considered as a clear evidence of temporal relationship, which we did not see in this study.
Got it. Given this is adjunctive treatment and will compete with atypical antipsychotics, these results, especially on remission, are particularly impressive. How are you thinking about eventual commercial positioning of HLP003, especially from a pricing perspective? Most of the psychedelic therapeutics point to SPRAVATO. Is that still a relevant comparator given you're playing a somewhat different ballgame?
Yeah, I would say it's a little early to talk specifically about pricing. Of course, SPRAVATO does provide, I think, a general framework in terms of pricing. But again, the actual product characteristics are, of course, very relevant. They're very relevant as you're having the discussions with payers, presenting those characteristics. Again, we're very excited about the data that we have to date, looking forward to then supplementing this dataset with the EMBRACE trial next year, and really think that those product characteristics will, of course, be key to the discussion. Again, the efficacy, durability, and favorable safety and tolerability profile. So, stay tuned, Sumant, as we move forward.
Thanks.
Thank you. Our next question comes from David Martin with Bloom Burton. Your line is open.
Yes, congratulations on the data. The treatment-related SAEs, the depression events, these are depressed patients, and you said they didn't respond to treatment. What would it be that made it deemed treatment-related?
Well, so treatment-related typically is an assessment that the clinician would make, and the clinician determined that it was, in their view, related to. Typically, lack of efficacy in a patient that is depressed, is not getting better also, would be considered as treatment-related. So it's up to the clinician. We do not question it. They know the patient best. They know the overall condition, and if they believe it's related, then that's how we assume it is.
Okay, great. Monitoring period. Have you honed in more so on how long the patients have to be monitored after the drug is dosed, and how does that compare versus your competitors?
Yeah, so we've collected these data, but that's not part of our top-line dataset. We will provide more information at a later date. What I can tell you is previously in our phase II, we saw about four to six hours of acute effects. It's too early to say, and once we have those data, we'll provide that information.
Okay. Just another quick one. Have you talked to the FDA about filing with one trial?
While FDA has the ability to approve with one trial, and of course, we're going to present these results to FDA, the standard case is what we've planned for with our full phase III program. We have our two pivotal trials, one completed, reporting today, one ongoing, as well as the long-term extension, which, as Amir Inamdar said, we believe will provide important information for clinicians in terms of dosing, any retreatment, et cetera. So, we're prepared for the standard review, and we believe we have everything ongoing necessary to meet the previous guidance we've communicated in terms of a 2028 potential NDA filing.
Okay, thank you. That's it for me.
Thank you. Our next question comes from Eddie Hickman with Guggenheim Securities. Your line is open.
Hi. Good morning, everyone, and congratulations on this great data. A couple from me. First, can you give us any detail on the discontinuation rates by week and any of the reasons, then how dropouts were handled throughout the study? I am also curious about the placebo rate. Obviously, these are adjunctive patients previously or already on SSRIs, and this placebo is a little bit higher than where you guided or where we would maybe expect it to be. As we think about having a dose-ranging study coming up, how should we think about how the placebo may act in future studies? Thanks.
Sure. I will let Amir speak to both discontinuation and placebo response. One comment before, I am really focused on the consistency of drug effect that we saw. We saw a very similar drug effect in phase III that we saw in phase II. It is very reassuring that as you expand from a smaller phase II trial into a large phase III, and all the additional clinical sites, et cetera, to see that consistency of drug effect, we are really pleased with that, frankly. Amir, if you want to talk about discontinuation and placebo?
Yeah. We generally saw low discontinuation rate in this study, and we had only two discontinuations due to AEs. In terms of the placebo response, placebo response has always been a challenge in depression trials. Despite this placebo response, we have demonstrated a very large effect size. In particular, as Michael said, given that HLP003 was administered adjunctive to patients who were already on their background antidepressants, so we are showing this large effect on top of whatever benefit patients are receiving from their baseline treatment. As Michael again said, we are also very pleased that the drug response we saw in phase II in a smaller study has consistently translated into this large phase III trial. That gives us confidence for future trial outcomes. Look, placebo response can be due to a number of non-specific clinical trial factors that are typically associated with clinical trial conduct.
In our trial, the placebo response may be due to lack of functional unblinding as a result of all of the measures we put into place, such as the independent blinded raters, the firewalling of access to patient data at site level, as well as the way we managed expectations from patients during the informed consent process.
Very helpful. Then one just final question. That day two result is pretty striking with the five-point separation being in line with what you sort of were expecting for six weeks. Is there sort of any path to a rapid onset claim on the label given those data?
Yeah, look, I mean, we are equally excited, if not more, about that day two response. As you said, that five points, highly statistically significant, is something that we actually expected at the primary endpoint. We are going to share these data with the agency, and this will be a determination that the agency makes after review of data.
Thank you.
Thank you. Our next question comes from Patrick Trucchio with H.C. Wainwright & Co. Your line is open.
Thanks. Good morning, and congrats on this data. Just a couple of follow-ups. The first was, I was wondering, among the patients that had already responded after the first administration, what incremental benefit did the second dose provide, and could those findings perhaps support a more individualized regimen? Then I am wondering how EXTEND could establish the proportion of patients needing no further treatment versus one or more repeat doses, and how could that tell us more about an expected annual dosing frequency?
Yeah. So, in terms of the response with the second dose, our initial thinking was the second dose will ensure durability of results. What we are clearly seeing is that 7.6 points at the six weeks, that is carried out to the 12-week endpoint, at which we see about seven points improvement compared to placebo. So, we are happy that our strategy of a second dose provided that durability in data. We did not look at the incremental benefit as a separate endpoint in this study, but as I said, durability is something that we are very pleased with, and we are happy that we took that decision to add a second dose to ensure durability. Now, we are of course following up patients in EXTEND, and we will see how the durability of these initial two doses last in the long term over a period of one year.
What EXTEND will do is not only provide information on this initial durability, but it will also provide us information on the need for redosing, what that redosing interval will be, and what that redosing frequency will be. As you probably recall, in EXTEND, we allow patients up to three additional doses. At 12 weeks, we are seeing a pretty robust improvement. So we will see in EXTEND how that pans out and whether that is one or two additional doses. Those data will be available at the end of that study.
I think, Amir, the only thing that I would add to that is obviously in our phase II, we saw strong durability results out to a year. Of course, we are now in a larger phase III, and we will have to see how things play out in EXTEND. But of course, the results we are reporting today, we certainly view positively as we think about potential durability results in the EXTEND trial. Again, very pleased.
That's helpful. Just as a follow-up, just given the magnitude of the separation here from placebo, I'm wondering how you're thinking about the product profile that's emerging here and whether you would expect to secure coverage before atypical antipsychotic augmentation, as well, just positioning against some of the other psychedelic or psychedelic-like treatments that are in development now for MDD.
Yeah, as I try and remind people, of course, we're the only late-stage development program in the psychedelic space for the adjunctive treatment of MDD. In terms of how the discussions with payers will go and then how clinicians will view this, again, obviously, we need to see the results of the ongoing studies. Based on what we're disclosing to date, we're very pleased with these product characteristics, would anticipate that these would be very constructive discussions with payers as you think about all the comorbidities that are associated with depression. Here again, based on the data that we have so far, you've got the robust efficacy. You saw the durability out to 12 weeks, the mild to moderate AE profile. If you think about this in terms of patient benefit, patient compliance, I think that there's the potential for very constructive discussions with payers.
From the clinician's perspective, Patrick, if you think about what they have currently available as they're looking to prescribe adjunctively, I think as I said in my prepared remarks, clinicians really like to follow the adjunctive treatment paradigm rather than washing patient off of standard of care that they potentially getting at least some benefit from. Not remission, of course, but they're getting some benefit. To switch to a monotherapy, they need to go through that process of washing the patient off, starting over with a new monotherapy, given that depression is a complex disease state, patient may or may not respond to that new monotherapy. Clinicians really like the adjunctive approach to continue that patient, build on whatever benefit that they're getting from their standard of care, albeit insufficient, but build on that towards the path of remission.
They're looking at, okay, what are my options to prescribe adjunctively? Right now, they only have the five atypical antipsychotics that are indicated adjunctively. Again, we believe that an adjunctively indicated product like HLP003, with the characteristics that we've shown to date, would be very compelling as clinicians are making that treatment choice for their patients.
Terrific. Thanks so much.
Thank you. Our final question comes from Emily Field with Barclays. Your line is open.
Hi. Good morning, and thanks for taking my questions, and also congratulations on the data this morning. Thank you also so much on this call for broadening the context around these serious adverse events. I guess, I just had a higher-level question for Michael, given your experience at your prior companies in the field. Is there anything in the safety set of this data that you think would change the tenor of your discussions with regulators, with FDA, and/or may change what an eventual REMS would look like? Perhaps more that seeing some of these events just, I guess, comes with the territory in engaging in an adjunctive trial, which obviously, for reasons you've mentioned throughout the call, does have a lot of benefits with clinicians and the treatment pathway for patients as well. So, thank you.
Thank you, Emily. The short answer is no. We do not believe that anything that we've seen in the safety data to date would change or negatively impact our discussions with FDA. Again, as I think we've stated a few times, no new safety findings based on the data from APPROACH. As Amir said, this patient population, of course, suffering from depression, very serious condition, so a real significant unmet need here. Again, wouldn't view the results that we, in terms of any of the adverse events, as expected to impact the discussions with FDA. But Amir, any other context you want to add?
Yeah. Generally, this was well tolerated, right? We saw that most of the AEs were mild or moderate. They were largely confined to the day of dosing. We also saw a very limited number of discontinuations due to treatment, only two. There is really nothing in the safety tolerability profile that gives me pause. Of course, this is an investigational drug. We are still conducting a phase III program, and when the phase III program is complete, including EXTEND, which will provide us with important long-term safety information, we will have better characterized and fully characterized this compound's safety profile. But as of now, looking at what we've seen, we do not believe there is any new safety signal with this compound.
Thank you.
Thank you. This concludes the question-and-answer session. I would now like to turn it back to Michael Halstead for closing remarks.
Well, thank you very much to everyone for joining today. We are very pleased with the results that we are reporting today, and looking forward to moving ahead, executing on the remainder of this phase III program, and very excited about the potential for HLP003 to be an important new treatment in the adjunctive treatment of MDD. Thank you very much, and we look forward to providing additional updates as we move forward.
This concludes today's conference call. Thank you for participating. You may now disconnect.